Rucaparib

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, March 27, 2024
Toxicity, Ovarian cancer, BRCA, Mirvetuximab soravtansine, Partnership, Patient, Neoplasm, Cancer, Merck, Doctor of Philosophy, Olaparib, WNT, Niraparib, Jiangsu Hengrui Medicine, PARP, Therapy, Safety, Platinum, Interim, Rucaparib, Pharmaceutical industry

This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.

Key Points: 
  • This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
  • In addition, stenoparib is unique in its mechanism of action, inhibiting PARP as well as the novel cancer target, tankyrase.
  • Tankyrase inhibition would restrain the WNT pathway, which is commonly upregulated not only in ovarian cancers but in many other solid cancers.
  • Given the unique, dual mechanism of action for stenoparib—coupled with its favorable safety profile—stenoparib may represent the next-generation alternative in the evolving market for advanced ovarian cancer patients.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

Retrieved on: 
Monday, April 17, 2023
Orange County Convention Center, Panaveli, Bevacizumab, AACR, GAPDH, ATP, Quality of life, American Association for Cancer Research, Paclitaxel, Gynecologic Oncology (journal), Niraparib, Monroe Dunaway Anderson, Assistant, MD Anderson Cancer Center, HRMS, Olaparib, Patient, AKT, Translational research, University, Cancer, Ultra, MTT, HK2, Poster, Rucaparib, RNA interference, Reproductive medicine, Ovarian cancer, PARP, Therapy, Hand, Pharmaceutical industry

BERWYN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for the patients that receive them, today announced that positive data from the Company’s tumor cell selective and broadly active small molecule with a unique mechanism of action, GP-2250 (misetionamide), was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

Key Points: 
  • “The data generated by GP-2250 to date has continued to demonstrate promising treatment potential for cancers.
  • These findings are encouraging and provide valuable insight as we advance the development of GP-2250 for the treatment of ovarian cancer.
  • With this growing body of data, we look forward to further evaluating GP-2250’s potential in the treatment of ovarian cancer,” commented Greg Bosch, Chairman and CEO of Panavance Therapeutics.
  • Dr. Sood commented, “There remains a significant unmet need in treatment options for ovarian cancer.

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Ovarian cancer, DNA repair, Prostate cancer, NER, Rucaparib, Breast, Neoplasm, Prostate, Machine learning, HRR, DNA, Lung, Patient, Breast cancer, FDA, BRCA, PARP, Esophageal cancer, Stomach, Olaparib, Kidney, Pharmaceutical industry, Niraparib, Lantern

LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies.

Key Points: 
  • LP-100 also demonstrated synergy with the FDA-approved PARP inhibitors Olaparib, Rucaparib, and Niraparib in ovarian cancer cell line studies.
  • The observations from these studies are further supported by in-silico evaluation of LP-100 in combination with PARP inhibitors using Lantern’s AI platform, RADR®.
  • “The combined anti-tumor potency of LP-100 in combination with PARP inhibitors, strongly supports the pursuit of this development pathway for LP-100,” stated Panna Sharma, Lantern’s President and CEO.
  • Lantern believes the simultaneous exploitation of both these mechanisms will enhance the development opportunities for LP-100, while also expanding potential market opportunities for existing PARP inhibitors.

Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022

Retrieved on: 
Thursday, September 8, 2022
Brain, Center, EGFR, Cancer Research UK, European Society for Medical Oncology, Research, The Royal Marsden NHS Foundation Trust, Newag Dragon, Cancer, Systems biology, Immunoglobulin G, ESMO, Drug development, HER2, Institute of Cancer Research, The Institute, Temozolomide, Translation, RAD, United Kingdom, HER3, Efficiency, Risk, NRG1, Drug discovery, Prostate cancer, Ovarian cancer, Royal Marsden Hospital, Patient, Cancer research, Rucaparib, Pharmaceutical industry

Hummingbird Bioscience management will attend ESMO 2022, which takes place in Paris from 9-13 September 2022.

Key Points: 
  • Hummingbird Bioscience management will attend ESMO 2022, which takes place in Paris from 9-13 September 2022.
  • The trial began enrolling in October 2021 and is ongoing in the UK.
  • The trial in progress poster will summarize the Phase 1 clinical trial design for HMBD-001 ( NCT05057013 ).
  • Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases.

Global PARP Inhibitors Cancer Therapy Market Report 2022-2028: Patent Expiration, Pricing, Dosage, Sales Analysis, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Olaparib, Fallopian tube cancer, Immunotherapy, Radiation, PARP, Company, Protein, Research, DNA repair, EMA, Lists of World Heritage Sites, Survival, PI3K, Patent, Niraparib, C1-inhibitor, Breast cancer, Peritonitis, Cancer, Indication, Rucaparib, Pancreatic cancer, Therapy, Global, Ovarian cancer, US FDA, DDR, Growth, Patient, Risk, DNA, MEK, CDK, Enzyme, Strategic planning, ADP, Pharmaceutical industry, Vaccine, Talazoparib, Carcinogenesis

The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors.
  • Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer.
  • "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report highlights:
    Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
    Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
    Regional Analysis Based On Drug Approvals: US, Europe, China & Japan
    3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair

Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, June 1, 2022
Diamond, Leadership, Achievement, Large-cell lung carcinoma, Company, Rucaparib, Program, Board of directors, EGFR, Glioblastoma, M26 Modular Accessory Shotgun System, First Pavlov State Medical University of St. Petersburg, Immunity (medical), Roche, Gaps, Cancer, ImClone Systems, Senior, GBM, Investigational New Drug, Research institute, Nasdaq, Ovarian cancer, Growth, Eli Lilly and Company, Â, Patient, GLOBE, Private Securities Litigation Reform Act, MAP, NEW, Clovis Oncology, Board, Drug discovery, Merck, NSCLC, Homologous recombination, U.S. Securities and Exchange Commission, Hematology, Black Diamond, Pharmaceutical industry, Risk management, IND

CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer. In conjunction with the appointment of Dr. Yurasov, Karsten Witt, M.D., is transitioning from his current role as the Company’s Interim Chief Medical Officer to a clinical advisory role.

Key Points: 
  • and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer.
  • We are delighted to welcome Sergey to Black Diamond as Chief Medical Officer.
  • Dr. Yurasov joins Black Diamond Therapeutics from Nuvation Bio, an oncology therapeutics company.
  • Dr. Yurasov succeeds Dr. Witt, who was Black Diamonds founding Chief Medical Officer and will continue to support the Company in an advisory capacity.